Setting Realistic Expectations Before You Start
One of the most important conversations in hormone therapy happens before the first prescription is written: what to expect, when to expect it, and what changes will require patience versus what changes should be felt relatively quickly. Patients who understand the timeline for hormone therapy have better outcomes — not because the timeline is faster, but because they are less likely to give up during the phase before full benefits are established.
Hormone therapy is not a switch that flips overnight. It is a process of biological recalibration — one that unfolds across weeks and months as cells, tissues, and systems respond to restored hormonal signaling. Here is a realistic, evidence-based timeline for the most common therapies offered at Multigen Wellness.
Testosterone Replacement Therapy (TRT) — Men
Weeks 1–2: Most men notice early shifts in sleep quality and energy within the first 1–2 weeks. Some describe a subtle but noticeable “lift” in mood and motivation. These early effects reflect the nervous system’s relatively rapid response to androgen receptor stimulation — particularly in mood-regulating brain circuits.
Weeks 3–6: Libido typically begins to improve in week 3–4. Mental clarity (sometimes called the “fog lifting”) is commonly reported. Morning erections return in many men. Energy becomes more consistent throughout the day.
Months 2–3: Physical changes become apparent. Muscle mass begins increasing in response to training — the anabolic environment restored by optimal testosterone significantly improves protein synthesis. Body fat begins declining, particularly from the abdomen. Confidence and social drive often improve noticeably.
Months 3–6: Full body composition changes are established. Hematocrit (red blood cells) has reached its new equilibrium. If an aromatase inhibitor was added, estradiol has stabilized. Most patients feel “fully optimized” by month 4–6.
Long-term (6–24 months): Bone density recovers (measurable by DEXA scan at 12+ months). Insulin sensitivity improvements are established. Continued body composition benefits with sustained training.
Women’s Hormone Therapy (HRT)
Weeks 1–3: Hot flash frequency and severity typically begin reducing within 2–3 weeks of starting estradiol. Sleep improvement often begins early, particularly if progesterone is started — its sedative metabolites produce noticeable sleep improvement within 1–2 weeks for many women.
Month 1–2: Vaginal dryness improves (particularly with local vaginal estrogen). Mood stabilizes as the erratic estrogen fluctuations of perimenopause are smoothed. Brain fog begins clearing.
Months 2–4: Full vasomotor symptom control is typically established. Body composition changes (reduced visceral fat) begin. Sexual desire, arousal, and satisfaction improve. Skin and collagen changes begin — more gradual than other effects.
Long-term: Bone density protection, cardiovascular benefits, and cognitive effects accumulate over years of therapy. These are preventive benefits that cannot be “felt” but are measurable and clinically significant.
Semaglutide (Medical Weight Loss)
Weeks 1–4: Reduced appetite and food cravings, often described as “not thinking about food constantly” for the first time in years. Weight loss of 2–4 pounds in the first month is typical at the starting dose.
Months 1–3: Dose is titrated gradually (typically over 16–20 weeks to full therapeutic dose). Weight loss accelerates with each dose increase. Average loss of 1–2 pounds per week at therapeutic doses.
Months 3–6: Maximum weight loss rate typically reached. Blood glucose, blood pressure, and lipid improvements become measurable. Total weight loss of 10–15% body weight by month 6 is typical.
Months 6–12+: Continued weight loss to 15–20% total body weight by 12 months in responsive patients. Weight maintenance phase begins with lowest effective dose.
To discuss your specific timeline and what to expect from your personalized protocol, call Multigen Wellness at (800) 259-0015. Telehealth appointments available throughout the week.